Symbols

SPRY

ARS Pharmaceuticals·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 0

Ample Liquidity

High Gross Profit Margin

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SPRY

Ars Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company developing innovative treatments for severe allergic reactions

Industry

Pharmaceutical

Established Date

01/04/2016

Listing Date

12/04/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

158

Fiscal Year Ends

12-31

Website

www.ars-pharma.com

Security Type

Common stock

Office address

11682 El Camino Real, Suite 300, San Diego, California 92130

Business

Introduction

ARS Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on January 4, 2016. The company is a biopharmaceutical company focused on developing novel, potentially best-in-class product candidates, neffy for the emergency treatment of type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail that allows neffy to deliver injection-like epinephrine absorption in small doses, easy to carry, easy to use, fast to administer and reliable nasal sprays.

Company Financials

EPS

SPRY has released its 2025 Q4 earnings. EPS was reported at -0.41, versus the expected -0.42, beating expectations. The chart below visualizes how SPRY has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SPRY has released its 2025 Q4 earnings report, with revenue of 28.09M, reflecting a YoY change of -67.56%, and net profit of -41.32M, showing a YoY change of -182.76%. The Sankey diagram below clearly presents SPRY's revenue sources and cost distribution.